Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. President Donald Trump wrote in a Truth Social post on Sunday U.S.

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

Prime Minister Dr Mostafa Madbouly chaired a meeting on Wednesday, April 15, 2026, to review the progress of the "Ras El Hekma" and "Shams El Hekma" projects on the North Coast. Madbouly emphasized ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

Think you've got what it takes to land your dream date? If so, congratulations! We send our best wedding wishes to you and your other half. But if your game could use a bit of work, we've got a ...

With the two-week ceasefire between the United States and Iran set to expire soon, both sides are weighing whether they can turn the fragile truce into a permanent end to a conflict that has killed ...

US Navy Secretary John Phelan was abruptly removed from his role while the Navy was enforcing a blockade in the Strait of Hormuz during heightened tensions with Iran. Accounts attribute the dismissal ...